Skip to main content
. 2024 Aug 14;10(9):3358–3367. doi: 10.1021/acsinfecdis.4c00461

Figure 3.

Figure 3

SQ109 displays ex vivo activity on African field isolates. (A) Dose–response analysis of SQ109 on clinical isolates SB03 and SB05 in comparison to lab-adapted NF54 P. falciparum parasites. Data are from at least 2 independent biological repeats, mean ± SE indicated, * P < 0.05 is indicated. (B) IC50 for SQ109 analogs 13 and 19 against a contemporary African field isolate SB05. IC50 of 19 on NF54: 0.2 vs on SB05: 0.95 ± 0.31 μM; IC50 of 13 on NF54: 0.98 ± 0.08 μM vs on SB5:0.49 ± 0.09 μM, * P < 0.05 is indicated.